Partial AUCs in Long-Acting Injectables: Rationale, Challenges, Variability, Usefulness, and Clinical Relevance
Regulatory authorities typically require bioequivalence to be demonstrated by comparing pharmacokinetic parameters like area under the plasma concentration-time curve (AUC) and maximum plasma concentration (C<sub>max</sub>). Because in certain cases, AUC and C<sub>max</sub> a...
Saved in:
Main Authors: | Georgia Tsakiridou, Maria-Faidra-Galini Angelerou, Panagiotis Efentakis, Antonios Margaritis, Antigoni-Maria Papanastasiou, Lida Kalantzi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-12-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/17/1/21 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pimobendan oral solution is bioequivalent to pimobendan chewable tablets in beagle dogs
by: Olaf Kuhlmann, et al.
Published: (2025-01-01) -
A multicenter, randomized, open label, two formulation, crossover bioequivalence trial of doxorubicin hydrochloride liposomal injection in Chinese patients with metastatic breast cancer
by: Jingshu Wang, et al.
Published: (2025-01-01) -
Patients' perspectives on buprenorphine subcutaneous implant: a case series
by: Claudio Pierlorenzi, et al.
Published: (2024-04-01) -
Are all tuberculosis deaths correctly attributed due to tuberculosis? Analysis of causes of death (COD) using verbal autopsy: A cross-sectional study in Puducherry
by: Reenaa Mohan, et al.
Published: (2025-01-01) -
Multiclass Supervised Learning Approach for SAR-COV2 Severity and Scope Prediction: SC2SSP Framework
by: Shaik Khasim Saheb, et al.
Published: (2025-01-01)